<DOC>
	<DOC>NCT00965497</DOC>
	<brief_summary>The purpose of this study is to see if escitalopram (Lexapro) improves symptoms of major depressive disorder in patients who have ALS or MS.</brief_summary>
	<brief_title>Escitalopram (Lexapro) for Depression MS or ALS</brief_title>
	<detailed_description>This eight-week study aims to assess the effectiveness and tolerability of escitalopram in improving symptoms of Major Depression in patients with Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS) as measured by the HAM-D. In addition, the study will assess improvement in the quality of life in patients with Major Depression and ALS or MS.</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Patients between 18 and 70 years of age with documented ALS or MS, DSMIV episode of nonpsychotic Major Depression, â‰¥14 score on the 17item HAMD, Ability to give informed consent. History of psychotic disorders, Psychotic depression, Bipolar depression, Suicide risk, History of substance abuse in the previous 6 months, History of unstable medical disorders, Pregnancy or planning for pregnancy, Severity of ALS or MS that limits participating in the study protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>ALS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>Major Depression</keyword>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>antidepressants</keyword>
	<keyword>Escitalopram</keyword>
	<keyword>Lexapro</keyword>
</DOC>